Industry, academic and government
Inovio has forged partnerships with pharma companies, government agencies and leading academic institutions to support the development of synthetic vaccines delivered via Inovio’s electroporation technology in many disease areas. Our strategy is to focus on our core expertise, conducting R&D and clinical development to achieve proof of principle of SynCon® vaccine products, and leave late-stage clinical development and commercialization to partners. We currently have advancing discussions with funding agencies and pharma/vaccine companies with the intent of securing funding and sponsorship for R&D and early clinical studies as well as more comprehensive development and partnering relationships.
University of Pennsylvania (UPenn)
Inovio’s partnership with the University of Pennsylvania is the major source of Inovio’s synthetic vaccine research and development. The underlying technology was developed in the laboratory of Professor David B. Weiner, Ph.D., at UPenn. Dr. Weiner is a pioneer in the field of DNA vaccines and serves as chairman of Inovio’s Scientific Advisory Board.
In 2007, Inovio (through VGX Pharmaceuticals, with which it merged in 2009) entered into an original research agreement with UPenn. The Company subsequently licensed from UPenn exclusive worldwide rights to develop a number of DNA plasmids and constructs with the potential to treat and/or prevent human immunodeficiency virus (HIV); hepatitis C virus (HCV); human papilloma virus (HPV), and influenza, and later an amended agreement adding novel adjuvants to enhance the effectiveness of DNA vaccines.
In 2011, Inovio expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against prostate cancer, CMV (cytomegalovirus), malaria, hepatitis B, RSV (respiratory syncytial virus), and MRSA (methicillin-resistant staphylococcus aureus). The amendment also encompassed a new optimized IL-12 cytokine gene adjuvant. These new DNA vaccines and technology were developed in the University of Pennsylvania laboratory of Professor David B. Weiner.
The University of Pennsylvania has also conducted clinical studies for Inovio's PENNVAX®-B HIV DNA vaccine in a therapeutic setting.
Merck & Co.
Under a 2004 license agreement, Merck & Co. holds worldwide non-exclusive rights to use Inovio's electroporation technology for intramuscular delivery of certain proprietary DNA vaccines. Inovio received an upfront payment and has received $4 million in milestone payments. Inovio is eligible to receive milestone payments, development fees, and royalties on products commercialized under the agreement, which also includes a supply agreement. To date, Merck has filed two Investigational New Drug Applications (INDs) for product candidates targeting various cancers using Inovio’s electroporation technology.
University of Southampton
The University of Southampton (UK) is advancing an investigator-sponsored clinical study of its leukemia DNA vaccine using Inovio's electroporation delivery technology.
The university previously completed an investigator-sponsored clinical study using Inovio's electroporation delivery technology in conjunction with a DNA-based vaccine against prostate cancer. Significant antibody and T-cell responses in humans were reported reported in a scientific paper published in Nature Reviews Cancer.
ChronTech AS is advancing a Phase II clinical study for a hepatitis C virus DNA vaccine using Inovio's EP technology.
HIV Vaccine Trials Network
The HIV Vaccine Trials Network (HVTN) is currently funding and conducting clinical trials of Inovio's PENNVAX®-B HIV DNA vaccine candidate.
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health is providing $23.5 million of funding over seven years (ending 2015), including a base period and follow-on option years, to develop Inovio's PENNVAX®-GP vaccine candidate targeting HIV clades A and C and its novel intradermal electroporation (ID-EP) technology.
U.S. Military HIV Research Program
The U.S. Military HIV Research Program (MHRP) is conducting an NIAID-sponsored Phase I study, called RV262, to evaluate a combination DNA prime (PENNVAX®-G)/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.
PATH Malaria Vaccine Initiative
The PATH Malaria Vaccine Initiative (MVI), established in 1999 through a grant from the Bill & Melinda Gates Foundation, is funding preclinical development of Inovio's SynCon® synthetic vaccine with respect to malaria.
U.S. Department of Homeland Security
Inovio entered into a Cooperative Research and Development Agreement with the US Department of Homeland Security Science and Technology Directorate Plum Island Animal Disease Center. This collaboration is evaluating the efficacy of Inovio's SynCon® vaccines for foot & mouth disease in important animal models including cattle, sheep, and pigs.
National Cancer Institute
Under a 2007 co-development agreement with Inovio, the National Cancer Institute is evaluating novel HIV constructs in non-human primates, cytokine genes as vaccine adjuvants (immune system stimulants), and possibly anticancer therapies delivered using Inovio's electroporation-mediated DNA delivery technology.
Page 'Breadcrumb' Navigation